Issue Date: May 2, 2011
Lilly And Medtronic In Parkinson’s Pact
Eli Lilly & Co. has joined with Minneapolis-based device maker Medtronic to deliver a neurotrophic-factor-based therapy in the brains of people with Parkinson’s disease. Lilly has biosynthetically engineered a variant of glial-cell-derived neurotrophic factor (GDNF), a protein that promotes the growth and survival of brain cells. In the past, GDNF was difficult to administer as a gene therapy because of its inability to cross the blood-brain barrier. Under the collaboration, Medtronic will use its implantable drug infusion system technology to deliver the Lilly compound.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society